Umer Raffat, Evercore ISI’s Chief Bio-Pharma Analyst, was interviewed on CNBC’s Closing Bell this afternoon/Tue. Oct. 10; and, he is/has been ranked as the Number One Specialty, Bio-Pharma Analyst by Institutional Investor — each year for the past three years.
Mr. Raffat’s #1 pick in both the large cap, and small cap bio-pharma sectors were:
Allergan (AGN) in the large-cap space; he has an Outperform Rating on its stock and a $271 price target. AGN closed today (Tue.) up $4.48, or +2.21 percent to $207.42. If he is right, there is a lot of upside here.
Dermira (DERM) Pharmaceuticals, which he says has huge/blockbuster potential in the first quarter of 2018, as the company is currently conducting Phase III Clinical Trials for their acme drug. He has an Outperform Rating on the company’s stock, with a target price of $48. DERM shares closed today up $1.43, or +5.28 percent to $28.67. Mr. Raffat is very optimistic/bullish on Dermira’s Phase III Trials because their Phase II Trials “met both the core; and, primary end-points.”
Obviously, no guarantees. He won’t always be right. Having said that, I may take positions in both at tomorrow’s/Wed.’s open. Whatever you decide, be sure to do your own due diligence and homework; and understand your risk tolerance and time horizon. V/R, RCP, www.fortunascorner.com